Skip to content

Role of the Chemical Environment in the Pathogenesis of Inflammatory Bowel Disease

Role of the Chemical Environment in the Pathogenesis of Inflammatory Bowel Disease

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03376230
Acronym
CHIMICI
Enrollment
148
Registered
2017-12-18
Start date
2010-02-28
Completion date
2019-01-24
Last updated
2019-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Diseases

Keywords

Environmental risk factors, Xenobiotic detoxification

Brief summary

Inflammatory Bowel Diseases (IBD) including Crohn's disease and ulcerative colitis are multifactorial diseases leading to chronic inflammation of intestinal mucosa. Their etiology is still unknown. Recently, major advances in the understanding of their pathophysiology have allowed to define them as heterogenic polygenic diseases, occurring in genetically susceptible patients. However, the whole genetic susceptibility does not explain the development of IBD and several data argue in favor of the involvement of environmental factors, which remain to be identified. The aims of this clinical trial are: 1. As main objective: To determine the effects of environmental pollutants on intestinal homeostasis and particularly on inflammatory process and endoplasmic reticulum stress. 2. As secondary objective, to assess in human the genetic susceptibility of intestinal mucosa to environmental chemical compounds (I.e. xenobiotics), its interindividual variability, and its potential involvement in the pathogenesis of IBD.

Interventions

OTHERCollect of blood, urines, and intestinal biopsies

Sponsors

University Hospital, Lille
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

1. Patients who are at least 18 years old 2. Has Crohn's disease or ulcerative colitis, diagnosed, confirmed by radiological and / or endoscopic examination within 4 years or Control patient not suffering from inflammatory bowel disease (patient with abdominal pain and / or persistent diarrhea, or patient requiring coloscopy for cancer of the digestive tract diagnosis) 3. Patients requiring coloscopy as part of their medical follow-up 4. Social insured.

Exclusion criteria

1. Pregnant women 2. Breastfeeding women 3. People in emergency 4. Persons unable to understand, read and / or sign informed consent 5. Patients who recently had an intercurrent episode (eg recent diarrhea ...) 6. Persons deprived of their liberty 7. Persons protected by a legal protection status

Design outcomes

Primary

MeasureTime frame
Comparison of inflammatory response of biopsies to pollutants between the 3 groups of patients.Baseline

Secondary

MeasureTime frame
Comparison of expression pattern of genes involved in xenobiotics detoxification in intestinal mucosa in between the 3 groups of patients.Baseline

Other

MeasureTime frame
Study of molecular origin and consequences of the genetic variability observed.Baseline

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026